Cindy's first-half sales of $500 million in the second quarter were close to O-drug full year.

Pharmaceutical Network August 3, with cinda bio PD-1 sales results announced, a new PD-1 market battle is about to come to an early date.
for the huge PD-1 market, capacity, indications, the final return is not the past.
400 million in the first quarter and 500 million in the second quarter, Cinda PD-1 sales in the first half of this year have been close to the full year of last year's 1 billion yuan, but also close to O drug 2019 sales in China, domestic PD-1 growth rate again refreshing.
at the same time, is also opening the gap, Junshi PD-1 Q1 sales this year is about 172 million yuan, sales in 2019 774 million yuan.
Baiji Shenzhou PD-1 was only listed for sale in March this year, with quarterly sales (including distributors) of about 150 million yuan.
currently, a total of six PD-1 products have been approved and commercialized in China.
, Societe Generale expects China's PD-1/PD-L1 inhibitor market to experience rapid growth, reaching RMB66.4 billion in 2023, with a COMPOUND growth rate of 133.5 percent from 2018 to 2023, as the growing types of indications and patient education increase.
domestic PD-1 in addition to the four listed, there are four will be listed, as well as a number of clinical phase 2 companies.
and 4 domestic PD-1 pricing strategy is not much different, the first year costs are 10 to 11 million, so, in the next domestic PD-1 battle, the most important thing is what? Wu Xiaobin, general manager of Baiji Shenzhou China, has previously said publicly that the PD-1 competition is not about price, but production capacity.
in addition to mass production, there is a consensus in the industry is the proof of adaptation.
01 Capacity Dispute July 23, Cinda Bio announced that it intends to place 56.2 million shares with a net income of HK$2,788 million for the construction of Suzhou Dabershu II production facilities and additional capacity to match the company's growth.
previousproduction of the company's Sindi-Singli sing-ireactor, which is mainly produced using three sets of 1000L cans, and said that six sets of 3000L cans from the second phase of the production facility have been certified by GMP and are expected to be operational by June 2020.
this news, the second phase of production facilities may be affected by the outbreak has been delayed.
, Cinda has publicly stated its intention to start building four production lines with a capacity of 15,000L around 2021.
Junshi sales, although temporarily lagging behind several others, but in the production capacity of the construction is no less, last December, Junshi Lingang production base started anti-PD-1 single resistance and anti-PCSK9 single resistance trial production.
it is understood that the base in accordance with the International Drug Production Quality Management Practice (CGMP) for construction, the first phase of the project covers an area of 80 acres, a total construction area of 70,000 square meters, production capacity can reach 30,000L, and left a reserved workshop, estimated to cost 1.8 billion yuan.
Junshi to the benefit is 7200 yuan / 240mg. in addition
, the company has a production capacity of 3000L at its production base in Wujiang, Jiangsu Province.
in addition to the two local upstarts, Baiji Shenzhou is also preparing for capacity. Wang Xiaodong, founder of
Baiji Shenzhou, believes that no enterprise has the experience of mass production of antibody drugs, if The future PD-1 into health insurance, increase production capacity, to ensure that bulk production will become the key.
, as early as 2017, Baiji Shenzhou began to build a production base of biological drugs in Guangzhou, the first phase of the project was officially completed at the end of September last year, the total investment of the base is expected to exceed 2.3 billion yuan, covers an area of 100,000 square meters, focusing on commercial scale of macromolecular biopharmaceutical technology development and production, production capacity of about 8000 liters.
the total production capacity of the entire project is 24,000 liters.
what is the capacity of Hengrui, which has a strong sales capacity? According to HengRui previously disclosed that the company in 2020 has four 2000L production capacity for Carelli Beads, about 1.2 million bottles.
Hengrui's main Production Base for PD-1 is Suzhou Shengdia.
Shengdia's EIA report, released at the end of 2018, is proposed to add antibody raw fluid production capacity of 19440L.
light according to the capacity of the fermentation tank, after the expansion of Shengdia annual PD-1 should reach about 3 million bottles.
it is worth noting that the current domestic single production line is more than 2000 liters, only equivalent to the global giant pilot platform production level, so the cost of domestic biopharmaceutical slower room.
and health insurance is the driving force that prompted PD-1 manufacturers to reduce their prices and expand production, Cinda Bio as the only PD-1 manufacturer simply entering health insurance, there is the idea of building a single 15,000 liter production capacity of production line, also reasonable.
, however, will undoubtedly upgrade the PD-1 race.
02 Adaptation certificate and combination drug use are considered to be the next focus in the Fierce Battle of PD-1.
in order to obtain approval as soon as possible, quickly enter the market access channel, domestic pharmaceutical companies are first targeted at less competition, high success rate of small indications.
Cinda Sindili monotophox, Hengrui's Carelli Pearl monosar, Baiji Shenzhou's Terelli Zhu monosaral although the approval time is inconsistent, but the first approved adaptation certificate are classic Hodgkin's lymphoma (cHL), while the Redskins' Telepley monosarcant is melanoma.
but the key to the decisive is, who's the adaptation card to expand quickly, who's the adaptation card market space is large, and who's the joint drug more.
Hengrui Pharmaceuticals' Carelli Zhu singular resistance listed less than half a year, sales exceeded 1 billion yuan; Cinda Bio into health insurance, half-year sales close to the whole of last year, even close to O drug China last year sales;
in other words, Carilli Beads may have such a result because of sales ability, Cindy Singli sing-iles may be due to health insurance, but the next battle for the expansion of the certificate will be the key to closing the gap.
at present, Hengrui Pharmaceuticals has been approved four adaptation certificates, in addition to cHL, there are liver cancer, esophageal squamous cancer, non-squamous non-small cell lung cancer (joint treatment).
, lung and liver cancer are large proof of adaptation, the number of patients accounted for 25% and 21%, respectively.
, NSCLC accounts for about 85 percent of lung cancer, while non-scaly NSCLC accounts for 70 percent of non-small cell lung cancer.
Citic Capital Securities believes that lung cancer is the largest indication in the PD-1 market, is expected to occupy 40% of the PD-1 market share, the estimated market size of 16.829 billion yuan.
second, liver cancer, stomach cancer, esophageal cancer we expect to occupy the PD-1 market share of about 20% to 30%, the total market size is estimated to be 21.978 billion yuan.
, therefore, four enterprises in lung cancer adaptation certificate competition, in the scale of NSCLC, Cinda progress ahead, Baiji Shenzhou second.
up to now, Cinda, Baiji Shenzhou single medicine has been to clinical 3, Cinda submission time 2 months earlier than Baiji, joint treatment, Cinda, Hengrui, Baiji each have a clinical in the 3rd phase, however, the adaptation certificate junshi only 1 joint treatment.
non-scaly NSCLC, Hengrui and Baiji layout hot, of which Baiji's reilly beads monotodrug and a joint treatment has been clinical 3, HengRui in addition to a joint treatment has been approved, there are 2 joint treatment in 2 stages, Cinda and Junshi each have one.
liver cancer, HengRui progress first, Cinda first-line adaptation of the progress of the second.
Hengrui in addition to the approved single drug treatment plan, there are 2 joint treatment in 3 stages, 1 in the 2 stages, Cinda's 2 joint treatments are also clinical 3.
, in addition, Baiji and Junshi each have two.
stomach cancer and esophageal squamous cancer, Hengrui layout more, Baiji Shenzhou next, followed by Cinda and Junshi creatures.
Hengrui has 4 clinical trials for the joint treatment of stomach cancer ahead of schedule, 100 ji 3, esophageal squamous cancer on Hengrui is 3, Baiji is 4, Cinda 2.
summary, in addition to the current approval of the increase in the adaptation certificate, in the upcoming approval of the adaptation certificate or the progress of the clinical trials, whether it is also on the schedule and layout, Baiji Shenzhou and Hengrui Pharmaceuticals, Cinda Bio in the scale nSCLC progress ahead, other adaptation certificate layout second only to Hengrui and Baiji Shenzhou, Junshi layout is relatively narrow.
.